Revive Therapeutics Ltd.

As of March 31, 2026, Revive Therapeutics Ltd. carries a market capitalization of 15.25M, placing it among publicly traded companies globally. Its enterprise value stands at 15.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2026, Revive Therapeutics Ltd. has 435.68M shares outstanding.

These figures are as of March 31, 2026.

As of March 31, 2026, Revive Therapeutics Ltd. maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2026. Return on assets (ROA) is negative at -214.42, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 2.00, a quick read on workforce productivity versus industry peers.

As of the close on October 22, 2026, Revive Therapeutics Ltd.'s stock has gained approximately 33.33% over the past 52 weeks. The 50-day moving average sits at 0.03, while the 200-day moving average is 0.03.

Over the twelve months ended March 31, 2026, Revive Therapeutics Ltd. generated - - in revenue and converted that into -10.62M in net income, yielding earnings per share of -0.02. EBITDA reached -10.67M, while operating income came in at -1.30M.

As of March 31, 2026, Revive Therapeutics Ltd. holds 12,665.00 in cash and equivalents against 70,770.00 in total debt, resulting in a net debt position of 58,105.00. Total book value stands at -4.02M, with working capital of -4.01M providing operational flexibility.

Revive Therapeutics Ltd. produced -156,711.00 in operating cash flow over the twelve months ended March 31, 2026.

These figures cover the twelve months ended March 31, 2026. Free cash flow yield is negative at -1.04: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.81, meaning Revive Therapeutics Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Revive Therapeutics Ltd.'s most recent stock split took place on May 18, 2016 with a 11:14 split ratio.

As of March 31, 2026, Revive Therapeutics Ltd. has an Altman Z-Score of -418.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.